A Phase 1b Study to Assess the Anti-fatigability Effect of CK-2127107 in Elderly Male and Female Subjects With Limitations in Mobility
Phase of Trial: Phase I
Latest Information Update: 13 Nov 2018
At a glance
- Drugs Reldesemtiv (Primary)
- Indications Muscular atrophy
- Focus Therapeutic Use
- Sponsors Astellas Pharma
- 31 Oct 2018 Status changed to discontinued due to Lack of efficacy determined at interim analysis
- 05 Oct 2018 According to an Astellas Pharma, status changed from recruiting to suspended, because Independent Data Monitoring Committee determined that the pre-defined criteria for lack of efficacy of reldesemtiv had been met.
- 26 Sep 2018 Status changed from recruiting to active, no longer recruiting.